Status:
UNKNOWN
A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer
Lead Sponsor:
Shanghai Henlius Biotech
Conditions:
Small-cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study is conducted in patients with advanced metastatic small cell lung cancer (SCLC). This study includes a single arm: the patients will receive HLX07 combination therapy with HLX10 and chemoth...
Eligibility Criteria
Inclusion
- Histologically or cytologically diagnosed with ES-SCLC (according to the Veterans Administration Lung Study Group staging system)
- No prior systemic therapy for ES-SCLC
- Major organs are functioning well
- Participant must keep contraception
Exclusion
- Histologically or cytologically confirmed mixed SCLC
- Known history of severe allergy to any monoclonal antibody
- Known hypersensitivity to carboplatin or etoposide
- Pregnant or breastfeeding females
- Patients with a known history of psychotropic drug abuse or drug addiction
- Patients who have other factors that could lead to the early termination of this study based on the investigator's judgment
Key Trial Info
Start Date :
March 29 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 29 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05354700
Start Date
March 29 2023
End Date
May 29 2024
Last Update
May 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jilin Cancer Hospital
Changchun, Jilin, China, 130000